Replies to post #124622 on Anavex Life Sciences Corp (AVXL)

[plexrec]

samk.... the presentation of data from a preclinical study of ANAVEX 2-73 for potential use in multiple sclerosis. The poster will be presented by the study’s lead investigator, Robert Lisak, M.D., Professor of Neurology at Wayne State University School of Medicine (Detroit, Michigan) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)"------this will be what the abstract is all about !

[plexrec]

samk...more accurately.... "Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis
R.P. Lisak, Detroit, US"------will be the topic of the abstract !!!---sorry for previous post---correction!

[neiu]

The WSU event is not what the others have been talking about. There is a conference for MS in Paris from Oct 25-28 which will hold much larger implications in terms of any further movement between Anavex/MS/BIIB IF Anavex is part of the abstract that Lisak from Wayne State is presenting.

https://www.ectrims-congress.eu/2017.html

14:52 - 15:04 Sigma 1 receptor agonists as potential protective and reparative therapy
in multiple sclerosis
R.P. Lisak (Detroit, US)

http://www.professionalabstracts.com/ectrims2017/programme-ectrims2017.pdfe

Normal Abstracts: all abstracts accepted for MSParis2017 will be published on the congress website and in press releases as of 15 October 2017 (10 days prior to the congress as from 08.00 CET). Coverage of abstract data in satellite symposia or in press releases at the congress is permitted. However, additional data yet to be presented cannot be included.

https://www.ectrims-congress.eu/2017/press/embargo-policy.html

BTW...WSU event that you mentioned has nothing to do with Wayne State Univeristy. WSU is for Washington State University.

[nidan7500]

I thought 27th.